Special Guest · 8:00–8:15 AM PT
PG
Paul Grand · Medtech Innovator
World's largest nonprofit accelerator and competition for medtech, digital health, and diagnostics startups. Offers mentorship, funding, and networking with industry leaders, investors, and corporate partners.
Pitches · 8:15–9:30 AM PT
BMI OrganBank
Carrie DiMarzio, CEO · cdimarzio@bmiorganbank.com
↩ Previously pitched at Medical Mondays · April 15, 2024
BMI has developed a portable room-temperature organ preservation system. Unlike current products, which put kidneys into hibernation, the BMI device keeps kidneys active by simulating the heartbeat, nutrients and oxygen provided by a healthy human body. This allows kidneys to be assessed for viability and transported over much longer distances.
FDA Breakthrough Device · $4.4M of $6M closed (73%)
Round
$6M Convertible Note @ $12M cap
Closed
$4.4M of $6M (73%)
FDA milestone
FDA Breakthrough Device Designation
FDA timeline
Q3 2026 IDE submission
Other groups in round
Band of Angels · Park City Angels · Mid-Atlantic Bio Angels
DD package
Available from Golden Seeds
Traction: National Kidney Foundation Innovation Fund investment. Clinical trial budget $35M; working with CRO (CTI) to engage surgical centers and OPOs.
What they're looking for: Additional KOLs across surgical specialties. Hospital introductions for clinical trial sites.
After the session
Investor sentiment
High interest
11
Medium interest
10
No interest
1
Will be interested at next round
2
24 responses
Investor engagement
8
Invitations to connect
8
Invitations to apply
Novuson
Stuart Mitchell, CEO & Founder · sbmitchell@novuson.com
Novuson has developed a surgical energy platform that uses sound to reduce the excessive tissue damage created by current surgical energy devices. Novuson technology will make surgeries faster, safer, and more precise.
18 patents (16 US, 7 international) · Hoya Corp invested via Microline Surgical
Round
$3M Priced Round @ $12M valuation (409A)
Tranches
$1M regulatory · $2M commercialization
Closed / soft
$563K closed · $1M soft-circled · $3M PE term sheet
FDA milestone
Pre-clinical validated (swine model)
FDA timeline
6 mo to submission · ~90 day approval
DD package
Available from Keiretsu Forum & TEN Capital
Traction: Hoya Corp invested via Microline Surgical. Medbot R&D revenue contract. LOI from Tsalys (~$1M); additional LOI expected from BM (~$2M).
Beachhead: Direct sales to surgeon-owned ambulatory surgical centers (ASCs) in 27 states with smoke evacuation mandates. 5-year plan: 753 ASC accounts, $200M revenue by 2030.
What they're looking for: BOD & Medical Advisors, KOLs, and (in the near future) VP of Operations and VP of Marketing.
After the session
Investor Sentiment
Investor Engagement
12
Respondents
0
Invitations to connect
1
Invitations to apply
NovaScan
Craig Davis, CEO · cdavis@novascanllc.com
↩ Previously pitched at Medical Mondays · July 21, 2025
NovaScan is commercializing a low-cost, point-of-care cancer detection platform using biospectral impedance, with initial launch of MarginScan targeting the high-volume dermatologic surgery market.
$3.7M CPRIT grant · 96–97% FDA-accepted sens/spec
Round
$1M → expanding to $1.75M Convertible Note
Terms
$18M pre-money cap · 20% disc · 8% int · 10% warrant
Closed
Most of original $1M
CPRIT grant
$3.7M (breast cancer)
FDA milestone
FDA pre-sub validated · 96–97% sens/spec
FDA timeline
Submission late this fall · 110-patient trial · 6-week conservative
Commercial partnerships executed: Epredia (commercialization partner), PHC Holdings (10% equity manufacturer; commercial device built), Apridia (commercial channel), Avantik (Mohs derm channel).
Reimbursement leadership: Bob Cook (formerly Castle Biosciences, took the company to $1B) leads NovaScan’s reimbursement effort.
What they're looking for: KOL introductions (especially dermatology + breast cancer surgeons). Strategic channel conversations beyond Epredia and Avantik.
After the session
Investor Sentiment
Investor Engagement
22
Respondents
1
Invitations to connect
4
Invitations to apply